These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 13679471)
1. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Epstein M Nephrol Dial Transplant; 2003 Oct; 18(10):1984-92. PubMed ID: 13679471 [No Abstract] [Full Text] [Related]
2. Eplerenone for the treatment of cardiovascular disorders. Watanabe M; Krum H Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915 [TBL] [Abstract][Full Text] [Related]
3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Moore TD; Nawarskas JJ; Anderson JR Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934 [TBL] [Abstract][Full Text] [Related]
4. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Rogerson FM; Yao Y; Smith BJ; Fuller PJ Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912 [TBL] [Abstract][Full Text] [Related]
7. The role of aldosterone receptor blockade in the management of cardiovascular disease. Liew D; Krum H Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020 [TBL] [Abstract][Full Text] [Related]
19. The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. Dawson A; Davies JI; Struthers AD Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):29-36. PubMed ID: 15038411 [TBL] [Abstract][Full Text] [Related]
20. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Barnes BJ; Howard PA Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]